Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- RGLS
- Price
- 7.88
- Stock movement down
- -0.33 (-4.02%)
- Company name
- Regulus Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 516.14M
- Ent value
- 496.73M
- Price/Sales
- 1709.08
- Price/Book
- 5.95
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -50.96%
- 1 year return
- 232.49%
- 3 year return
- 49.87%
- 5 year return
- -3.47%
- 10 year return
- -39.86%
Last updated: 2025-06-22
DIVIDENDS
RGLS does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1709.08 |
| Price to Book | 5.95 |
| EV to Sales | 1644.79 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 65.50M |
| EPS (TTM) | -0.64 |
| FCF per share (TTM) | -0.56 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 302.00K |
| Gross profit (TTM) | 56.00K |
| Operating income (TTM) | -44.60M |
| Net income (TTM) | -41.63M |
| EPS (TTM) | -0.64 |
| EPS (1y forward) | -1.36 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 18.54% |
| Operating margin (TTM) | -14766.89% |
| Profit margin (TTM) | -13784.11% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 26.37M |
| Net receivables | 0.00 |
| Total current assets | 91.69M |
| Goodwill | 0.00 |
| Intangible assets | 25.00K |
| Property, plant and equipment | 2.05M |
| Total assets | 93.76M |
| Accounts payable | 792.00K |
| Short/Current long term debt | 476.00K |
| Total current liabilities | 6.48M |
| Total liabilities | 6.96M |
| Shareholder's equity | 86.81M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -35.95M |
| Capital expenditures (TTM) | 411.00K |
| Free cash flow (TTM) | -36.36M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -47.96% |
| Return on Assets | -44.40% |
| Return on Invested Capital | -47.96% |
| Cash Return on Invested Capital | -41.89% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 8.20 |
| Daily high | 8.24 |
| Daily low | 7.75 |
| Daily Volume | 17.0M |
| All-time high | 2649.60 |
| 1y analyst estimate | 10.33 |
| Beta | 1.63 |
| EPS (TTM) | -0.64 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| RGLS | S&P500 | |
| Current price drop from All-time high | -99.70% | -3.04% |
| Highest price drop | -99.97% | -56.47% |
| Date of highest drop | 27 Mar 2023 | 9 Mar 2009 |
| Avg drop from high | -80.02% | -11.04% |
| Avg time to new high | 67 days | 12 days |
| Max time to new high | 2669 days | 1805 days |
COMPANY DETAILS
Marketcap
516.14M
Marketcap category
Small-cap
Description
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Employees
32
Website
Investor relations
-
SEC filings
CEO
Joseph P. Hagan
Country
USA
City
San Diego
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner